Trial Profile

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Infigratinib (Primary) ; Fulvestrant; Iohexol; Iopamidol; Palbociclib; Tamoxifen
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Adverse reactions

Most Recent Events

21 Oct 2022 Status changed from active, no longer recruiting to discontinued.
18 Oct 2022 Status changed from recruiting to active, no longer recruiting.
16 Oct 2020 Planned End Date changed from 1 Dec 2023 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com